AlphaQuest LLC Acquires Shares of 32,251 ACADIA Pharmaceuticals Inc. $ACAD

AlphaQuest LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 32,251 shares of the biopharmaceutical company’s stock, valued at approximately $688,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Marshall Wace LLP raised its stake in ACADIA Pharmaceuticals by 496.2% in the second quarter. Marshall Wace LLP now owns 1,969,711 shares of the biopharmaceutical company’s stock valued at $42,487,000 after buying an additional 1,639,315 shares in the last quarter. Norges Bank purchased a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at about $31,679,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth about $13,024,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth about $7,257,000. Finally, Prudential Financial Inc. lifted its stake in ACADIA Pharmaceuticals by 93.3% during the second quarter. Prudential Financial Inc. now owns 685,477 shares of the biopharmaceutical company’s stock worth $14,786,000 after purchasing an additional 330,876 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Citigroup increased their price target on shares of ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Needham & Company LLC restated a “buy” rating and issued a $34.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, January 5th. Mizuho increased their target price on shares of ACADIA Pharmaceuticals from $24.00 to $29.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.25.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Analysts reaffirmed bullish ratings and raised price targets (Citizens/JMP $34 PT; HC Wainwright $37 PT), which supports upside potential if clinical/regulatory risks ease. Benzinga
• Positive Sentiment: Equity research pieces (Zacks) highlight ACAD as likely to beat upcoming earnings/estimates, underpinning near-term earnings-driven support for the stock. 5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
• Neutral Sentiment: Reported short-interest data in early February appears to show zero shares (likely a reporting anomaly) and gives no clear signal on short-seller pressure. (Data entry)
• Negative Sentiment: Acadia announced a negative CHMP trend vote on its trofinetide MAA for Rett syndrome and intends to seek re‑examination — this materially increases the timeline and regulatory uncertainty for EU approval and revenue upside. BusinessWire: Regulatory Update
• Negative Sentiment: Press coverage and market commentary stress the EU setback as a meaningful change to Acadia’s bull case, and the stock reacted with after‑hours declines. Yahoo: Bull Case Could Change
• Negative Sentiment: Additional reporting ties Acadia to broader regulatory scrutiny (FDA’s new “PreCheck” program referenced alongside other company setbacks), reinforcing near-term regulatory risk narratives. BioPharmaDive: FDA PreCheck / Setbacks
• Negative Sentiment: Market reaction articles document an after‑hours slump and coverage of share weakness following the EU news — amplifying short‑term selling pressure. MSN: After-hours Slump

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD opened at $24.76 on Wednesday. ACADIA Pharmaceuticals Inc. has a one year low of $13.40 and a one year high of $28.35. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of 15.97, a PEG ratio of 6.54 and a beta of 0.66. The company has a 50-day simple moving average of $26.54 and a 200-day simple moving average of $24.46.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.28. The firm had revenue of $278.63 million for the quarter, compared to analysts’ expectations of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 EPS. As a group, research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,084 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total value of $96,749.96. Following the transaction, the insider directly owned 25,058 shares in the company, valued at approximately $593,624.02. This trade represents a 14.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James M. Daly sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $22.37, for a total value of $671,100.00. Following the sale, the director owned 4,041 shares of the company’s stock, valued at $90,397.17. This trade represents a 88.13% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 44,346 shares of company stock worth $1,010,957. 28.30% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.